Pakistan, Oct. 24 -- The National Assembly was informed on Friday that Pakistan is facing a shortage of Apidra, a rapid-acting insulin manufactured by Sanofi, following a disruption at its German production facility. Parliamentary Secretary for Health Nelson Azeem said supplies had fallen from 3,500 kits to 1,000, with the manufacturing upgrade expected to take a year. His assurance that alternative products were available drew concern from MNA Syeda Amna Batool, who pointed out that substitutes cost at least 20 per cent more and many patients lacked access to doctors who could supervise a change in treatment. For people who depend on insulin every day, such assurances offer little comfort unless the medicine is within reach and affordabl...